Remarks: 51 Studies on HCQ, Hydroxychloriquine, and the data is in and its saying HCQ has Prophylactic Benefits & Safe, Effective Outpatient Treatment in the early stages produces great outcomes. Association of American Physicians and SurgeonsSEE URL: https://aapsonline.org/ are suing the FDA to get Hydroxychloriquine approved and released for use. AAPS v. FDASEE URL: https://aapsonline.org/judicial/aaps-v-fda-hcq-7-20-2020.pdf, No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.). FULL STORY HERE: https://www.4cmitv.com/2020/08/05/2020-aug-05-covid-hcq-fauci-gates-vaccine-tracers-and-markers/
AAPS HEADLINED: More Evidence Presented for Why Hydroxychloroquine Should be Made Available, in a New Court Filing by AAPS
This week the Association of American Physicians & Surgeons submitted additional evidence to a federal court for why interference with hydroxychloroquine (HCQ) should end by the Food & Drug Administration (FDA) and the Department of Health & Human Services (HHS), in AAPS v. FDASEE urL: https://aapsonline.org/judicial/aaps-v-fda-hcq-7-20-2020.pdf, No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.).
“As confirmed by another recent study of thousands of patients at the Henry Ford Health System in Michigan, HCQ is both very safe and highly effective in treating COVID-19, reducing mortality by 50%,”
AAPS informed the court in its filing. “Countries with underdeveloped health care systems are using HCQ early and attaining far lower mortality than in the United States, where [HHS and the FDA] impede access to HCQ.”
Yet most Americans are still unable to obtain HCQ for early treatment of COVID-19, and virtually no Americans are able to access it as preventive medicine. HCQ has been used safely for decades by travelers to protect against malaria, but Americans are dying from COVID-19 while HCQ is withheld from them.
“Citizens of the Philippines, Poland, Israel, and Turkey all have greater access to HCQ than American citizens do,” observes AAPS General Counsel Andrew Schlafly.
“In Venezuela, HCQ is available over the counter without a prescription, while in the United States pharmacists are prevented from filling prescriptions for HCQ.”
AAPS rebuts arguments presented by the FDA, which implied that medications are approved as safe only for certain conditions. In fact, HCQ and most medications have been approved without limitation, such that physicians can prescribe them for any off-label use.
Polish chemists have even showed the world how to synthesize HCQ from cheaply, widely available ingredients. The cost of this medication is less than a dollar a dose, in contrast with the very expensive alternatives being pushed by FDA officials.
In its filing, the FDA insisted that the public has no right to access nearly 100 million doses of HCQ which were donated to the Strategic National Stockpile. HHS is having that medication waste away while Americans are dying from COVID-19.
“In some areas of Central America, officials are even going door to door to distribute HCQ,” Andrew Schlafly adds. “These countries have been successful in limiting the mortality from COVID-19 to only a fraction of what it is in wealthier countries.”
AAPS filed this lawsuit to obtain legal redress in support of Trump, by ending the obstruction by the FDA of his policies that would save lives.
AAPS has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.
Original Source: Date-stamped: 2020 JUL 22 | Author: AAPS | Article Title: More Evidence Presented for Why Hydroxychloroquine Should be Made Available, in a New Court Filing | Article Link: aapsonline.org
AAPS HEADLINED: FDA Delays on HCQ Outpatient Approval Are Causing Deaths Daily
20,000 more Americans have died while the FDA has delayed since July 1 a new emergency use approval for outpatient use of hydroxychloroquine (HCQ) for COVID-19.
On July, 1 Henry Ford Hospital physicians and researchers in Detroit filed an urgent request to FDA Commissioner Dr. Stephen Hahn for a new outpatient Emergency Use Authorization (EUA) for FDA approval of HCQ to be used in early treatment for COVID-19.
Baylor Scott & White Heart and Vascular Institute in Dallas, issued an urgent appeal supporting the Henry Ford EUA application, based on their clinical study of prophylactic use of HCQ in their own medical workers. Baylor cardiologists emphasized there were no adverse cardiac outcomes in their own or the Ford study.
Henry Ford’s new clinical trial found an impressive 51% reduction in deaths if HCQ was begun within 24 hours of admission to hospital. An outpatient primary care study by Dr. Vladimir Zelenko, using HCQ, azithromycin and zinc given within less than 7 days of COVID-19 symptoms, showed approximately 80% decrease in deaths, and less than 1% of his patients needed to be admitted to hospital. These U.S. early intervention studies extraordinary results show how many lives can be saved with early HCQ treatment.
If the FDA had acted quickly on the Henry Ford and Baylor approval request for HCQ, we can reasonably consider that 16,000 lives could have been saved since July 1.
EUA applications do not have to take long to approve, when well documented rationale and supporting research is presented as Henry Ford team and Baylor cardiologists did.
HCQ is already an FDA-approved drug, unlike remdesivir, which had almost an immediate compassionate use authorization granted that has now been expanded for early use despite severe side effects. The former director of the FDA subagency BARDA, Rick Bright, Ph.D., submitted an EUA for HCQ approval for hospital use at 11:30 pm on March 28, 2020. Dr. Hahn’s approval was granted a little after midnight, March 29, 2020. Approval in about 30 minutes.
We have been waiting almost 30 days for Dr. Hahn to issue approval of the Henry Ford EUA application for outpatient use. Dr. Hahn has stated that we need more data. Henry Ford and Baylor doctors have already provided research documentation stronger than in Rick Bright’s March application, and included current COVID-19 studies from the U.S. and other countries.What amount of “data” will ever satisfy Dr. Hahn?
Laboratory studies published by the National Institutes of Health 15 years ago (2005) showed potent antiviral effects of chloroquine against SARS-CoV-1 to block the infection at the earliest stage. Anthony Fauci, who was working at NIH at that time, has to have known for the last 15-18 years that chloroquine and hydroxychloroquine are effective against SARS-Co-V-1, which shares 79% of the viral genome with SARS-CoV-2, the cause of COVID-19 disease.
It is appalling that so many more Americans have died, while the physician who is head of the FDA has dawdled on approving HCQ for an urgent new use in this pandemic. Dr. Hahn knows full well the 65-year track record of safety worldwide in patients of all ages, all ethnic groups, and even pregnant women and nursing mothers.
Doctors who are treating COVID-19 patients see lives being saved by cheap, safe, FDA-approved medicines—hydroxychloroquine, azithromycin, doxycycline.
IT IS CRUCIAL TO START HCQ EARLY; during days 1-7 of symptoms, for these key reasons:
• Early treatment is when HCQ works best two ways: to stop viral entry into our cells, and block the virus from multiplying using the cell’s machinery.
• The viral load explodes by day 6, and then can trigger an exaggerated inflammatory response called Cytokine Storm, which severely damages critical organs: lungs, kidneys, heart, brain, liver and intestines. This severe complication doesn’t occur in all COVID-19 patients, but often is fatal when it does.
• Early treatment keeps infected people from spreading the virus to others.
• Early treatment is crucial to keep people out of hospitals and off ventilators.
• Availability of early treatment is urgently needed to safely re-open businesses, schools, and churches, and help relieve public anxiety and fear.
Front-line doctors have been pleading with the FDA and State officials since March to open access to early treatment with HCQ.
The supply of HCQ has been ramped up to handle its use in early treatment of COVID. The Strategic National Stockpile has millions of doses deteriorating in government warehouses that are not being distributed because doctors are prevented from prescribing for outpatients with COVID-19.
FDA’s misleading statements about HCQ have led to dangerous, unprecedented restrictions on physicians’ off-label prescribing rights imposed by state governors, medical boards and pharmacy boards.
Generic HCQ with azithromycin or doxycycline plus zinc is taken by mouth.Total treatment cost is about $25-$30 cash price for the 5-7 day course used in COVID-19.
Remdesivir must be given intravenously to patients in hospital, at a cost of about $3,500. Its serious side effects include respiratory failure, the very condition it is supposed to treat. It has shown limited success: it shortened hospital stays by only 4 days and has not been clearly shown to reduce deaths.
Baylor’s study showing prophylactic benefits for hospital workers is profoundly important, not only for front-line medical workers, but also for law enforcement officers, paramedics, clergy, dentists/dental hygienists, truck drivers, food-processing workers, teachers, behavioral health professionals, factory and grocery store workers, flight attendants, and many others.
HCQ is a safe, effective outpatient treatment we have NOW. Physicians and patients need freedom to use it. Delays waiting for the “magic bullet” of a vaccine inevitably mean more deaths. Even IF we have a vaccine that works, we still need therapeutics, such as HCQ.
Testing is inaccurate and often unavailable, and HCQ dispensing must not be limited to persons with a positive test. Such limits also prevent prophylactic use. Governors and other officials must not be allowed to arbitrarily restrict life-saving HCQ treatment.
Continued shutdowns of businesses, schools, churches, and mandatory mask edicts are not controlling the epidemic. Meanwhile, these orders have eroded our constitutional freedoms, and devastated our economic, psychological, physical, and spiritual well-being.
Dr. Hahn’s FDA is costing more lives with its delay in removing the obstructions it created to prescribing safe, effective early HCQ treatment: deaths directly from COVID-19 and indirectly by destroying livelihoods and distributions of foods, goods and services required to sustain our lives.
Dr. Hahn, America needs you to act NOW.
Original Source: Date-stamped: 2020 JUL 28 | Author: Article Title: FDA Delays on HCQ Outpatient Approval Are Causing Deaths Daily | Article Link: aapsonline.org
Hashtags: #4cminewswire, #HCQ, #Hydroxychloriquine, #COVID19, #nCov19, #Coronavirus, #NovelCoronavirus, #4cminews, #4CMiTV, #4CM2020AUG05
Tags: 4cminewswire, HCQ, Hydroxychloriquine, COVID-19, nCov19, Coronavirus, Novel Coronavirus, 4cminews, 4CMiTV, #4CM2020AUG05
Raw Cut: Yes
Reporter Political Pundit Commentary: No
Edited by 4cm: Yes
4CMINEWS SOCIAL MEDIA:
Dailymotion & Facebook: DEFUNCT SOCIAL MEDIA PLATFORM
Original-Source: America Can We Talk?
Original-Source-Published: 2020 AUG 05,
MEDIA CLIP PROPERTIES:
Length: (00:19:30:00 minutes)
Size: (633 MB)
Frame-Rate kbps: 25.00
Data-Rate kbps: 4400
|↑1||SEE URL: https://aapsonline.org/|
|↑2||SEE URL: https://aapsonline.org/judicial/aaps-v-fda-hcq-7-20-2020.pdf|
|↑3||SEE urL: https://aapsonline.org/judicial/aaps-v-fda-hcq-7-20-2020.pdf|